Our data show that, in turn, increased IL11 and POSTNi4 respectively contribute to enhanced tumor initiation and resistance to therapy, thus providing original insights on the mechanism behind relapses in CRC patients that fail to respond to platinum-based CT. This evidence concerns the gene IL11 and neoplasm.